EMA Authorised: Evenity (romosozumab) — UCB Pharma S.A.

View source ↗

Summary

Evenity (romosozumab) has been authorised in the EU for osteoporosis. The marketing authorisation holder is UCB Pharma S.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Evenity (romosozumab)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis. MAH: UCB Pharma S.A.. Decision date: 06/05/2025